|Dr. William V. Williams M.D.||CEO, Pres & Director||N/A||N/A||N/A|
|Dr. Charles Louis Wiseman M.D., FACP||Founder & Director||N/A||N/A||N/A|
|Mr. Gadi Levin B.Com., C.A., M.B.A., CPA, MBA||CFO & Corp. Sec.||N/A||N/A||1973|
|Ms. Farrah Dean||Mang. of Corp. Devel.||N/A||N/A||N/A|
BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, develops personalized treatments for cancer. Its lead product candidate is Bria-IMT, a clinical trial in combination with pembrolizumab (KEYTRUDA; manufactured by Merck & Co., Inc.) for use in patients with breast cancer. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer patients; and BriaDX, its companion diagnostic test. Its preclinical small molecule program consists of protein kinase C delta inhibitors for cancer and fibrotic diseases. BriaCell Therapeutics Corp. has a clinical trial collaboration and supply agreement with Incyte Corporation for developing Bria-IMT with compounds for treating breast cancer. The company is headquartered in West Vancouver, Canada.
BriaCell Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.